Circulating tumor cells (CTC) detection: clinical impact and future directions.

Recent molecular and clinical studies have shown that invasion may occur very early in tumor development, thus emphasizing the potential importance of specific and sensitive detection of circulating tumor cells (CTC) and circulating tumor microemboli (CTM). The technical challenge in this field consists of finding "rare" tumor cells (just a few CTCs mixed with the approximately 10 million leukocytes and 5 billion erythrocytes in 1ml of blood) and being able to distinguish them from epithelial non-tumor cells and leukocytes. Many recent studies have discussed the clinical impact of detecting CTC/CTM. Although conflicting results have been obtained, these studies suggest the vast potential of CTC/CTM detection in cancer prognosis and follow up. However, the variable technical approaches which were used, as well as the number of millilitres of blood analyzed, the quality of sensitivity and specificity tests, the number of patients versus controls and the data interpretation make it very difficult to draw firm conclusions. A particularly important recent finding is that invasive tumor cells tend to loose their epithelial antigens by the epithelial to mesenchymal transition (EMT) process. Furthermore, it is known that non-tumor epithelial cells can also be present in blood. Thus, it appears that a reliable diagnostic identification of CTC and CTM cannot be based on the expression of epithelial-specific transcripts or antigens. Cytopathological examination of CTC/CTM, sensitively enriched from blood, represents a potentially useful alternative and can now be employed in routine analyses as a specific diagnostic assay, and be tested in large, blind, multicenter clinical trials. This basic approach can be complemented by immunological and molecular studies for further characterization of CTC/CTM and of their malignant potential. This review is aimed at helping oncologists critically evaluate past and future research work in this field. The interest in development and assessment of this noninvasive marker should lead to more effective and better tailored anticancer treatments for individual patients, thus resulting in their improved life expectancy.

[1]  Stephen A Bustin,et al.  Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis. , 2005, Clinical science.

[2]  A. Nobel,et al.  Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .

[3]  R. Eils,et al.  From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[4]  John Calvin Reed,et al.  Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. , 2005, Cancer research.

[5]  K. Pantel,et al.  Detection and molecular characterisation of disseminated tumour cells: implications for anti-cancer therapy. , 2005, Biochimica et biophysica acta.

[6]  N. Kröger,et al.  Specificity of reverse transcriptase polymerase chain reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro. , 1998, British Journal of Cancer.

[7]  G. Ayers,et al.  HER‐2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors , 2004, International journal of cancer.

[8]  L. Sobin,et al.  Classification of isolated tumor cells and micrometastasis , 2000 .

[9]  E. Thiel,et al.  Quantitative real‐time RT‐PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers , 2004, International journal of cancer.

[10]  Tanja Fehm,et al.  Circulating Tumor Cells in Patients with Breast Cancer Dormancy , 2004, Clinical Cancer Research.

[11]  Mario Pazzagli,et al.  Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection. , 2006, Human pathology.

[12]  G. Sauter,et al.  Changes in Cytoskeletal Protein Composition Indicative of an Epithelial-Mesenchymal Transition in Human Micrometastatic and Primary Breast Carcinoma Cells , 2005, Clinical Cancer Research.

[13]  P. Friedl,et al.  Tumour-cell invasion and migration: diversity and escape mechanisms , 2003, Nature Reviews Cancer.

[14]  R. Hill,et al.  Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[15]  I sabel Mortara,et al.  International Union against Cancer , 1938, Nature.

[16]  F. Kelleher,et al.  Common critical pathways in embryogenesis and cancer , 2006, Acta oncologica.

[17]  J. Goeminne,et al.  Pitfalls in the detection of disseminated non-hematological tumor cells. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  M. Dowsett,et al.  Circulating tumour cells in breast cancer. , 2004, The Lancet. Oncology.

[19]  E. Kubista,et al.  Circulating breast cancer cells are frequently apoptotic. , 2001, The American journal of pathology.

[20]  Tanja Fehm,et al.  Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  R. Weinberg,et al.  Exploring a new twist on tumor metastasis. , 2006, Cancer research.

[22]  E. Kohn,et al.  Molecular insights into cancer invasion: strategies for prevention and intervention. , 1995, Cancer research.

[23]  K. Pachmann.  Longtime Recirculating Tumor Cells in Breast Cancer Patients , 2005, Clinical Cancer Research.

[24]  S. Dudoit,et al.  Ischemic preconditioning modulates the expression of several genes, leading to the overproduction of IL‐1Ra, iNOS, and Bcl‐2 in a human model of liver ischemia‐reperfusion , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[26]  Hellmut Samonigg,et al.  Comparison of two methods for enumerating circulating tumor cells in carcinoma patients , 2005, Cytometry. Part B, Clinical cytometry.

[27]  C Hollmann,et al.  DETECTION OF DISSEMINATED TUMOR CELLS IN PERIPHERAL BLOOD , 2005, Critical reviews in clinical laboratory sciences.

[28]  C. Bréchot,et al.  Spontaneous and iatrogenic spreading of liver‐derived cells into peripheral blood of patients with primary liver cancer , 1997, Hepatology.

[29]  M. Dowsett,et al.  Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques , 2005, British Journal of Cancer.

[30]  M. Fiegl,et al.  Mammaglobin Gene Expression: A Superior Marker of Breast Cancer Cells in Peripheral Blood in Comparison to Epidermal-Growth-Factor Receptor and Cytokeratin-19 , 2000, Laboratory Investigation.

[31]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[32]  K. Schütze,et al.  Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells. , 2000, The American journal of pathology.

[33]  K. Pienta,et al.  Global gene expression profiling of circulating tumor cells. , 2005, Cancer research.

[34]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[35]  Ulrich Keilholz,et al.  Circulating tumor cells: the 'leukemic phase' of solid cancers. , 2006, Trends in molecular medicine.

[36]  B. Tombal,et al.  Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in blood cells: implications for the detection of hematogenous prostate cells and standardization. , 1998, Clinical chemistry.

[37]  K. Pienta,et al.  Apoptosis of circulating tumor cells in prostate cancer patients , 2004, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[38]  Pier Paolo Delsanto,et al.  Insights from a novel tumor model: Indications for a quantitative link between tumor growth and invasion. , 2003, Medical hypotheses.

[39]  John Condeelis,et al.  Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis , 2006, Cell.

[40]  E. Lander,et al.  A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.

[41]  A. Al-Mehdi,et al.  Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis , 2000, Nature Medicine.

[42]  Mitch Dowsett,et al.  Cell filtration‐laser scanning cytometry for the characterisation of circulating breast cancer cells , 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[43]  P. Kober,et al.  The relevance of RT-PCR detection of disseminated tumour cells is hampered by the expression of markers regarded as tumour-specific in activated lymphocytes. , 2006, European journal of cancer.

[44]  J. Concordet,et al.  Illegitimate transcription: transcription of any gene in any cell type. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Thiery,et al.  Complex networks orchestrate epithelial–mesenchymal transitions , 2006, Nature Reviews Molecular Cell Biology.

[46]  J. Benson,et al.  Classification of isolated tumor cells and micrometastasis , 2000, Cancer.

[47]  V. Schirrmacher.  T-cell immunity in the induction and maintenance of a tumour dormant state. , 2001, Seminars in cancer biology.

[48]  René Bernards,et al.  A progression puzzle. , 2002, Nature.

[49]  A. Pileri,et al.  Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  G Kvalheim,et al.  Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. , 1999, Cytotherapy.

[51]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[52]  J R Siewert,et al.  Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood. , 2002, Cytometry.

[53]  N. Kröger,et al.  Interference of cytokeratin-20 and mammaglobin-reverse-transcriptase polymerase chain assays designed for the detection of disseminated cancer cells , 2001, Medical oncology.

[54]  A. Rajasekaran,et al.  Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. , 2006, Cancer research.

[55]  N. Brousse,et al.  Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence. , 2000, The Journal of urology.

[56]  B. Garicochea,et al.  Reverse transcriptase-polymerase chain reaction analysis of cytokeratin 19 expression in the peripheral blood mononuclear cells of normal female blood donors. , 1997, Molecular pathology : MP.

[57]  E. Dougherty,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[58]  K. Pienta,et al.  Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. , 2003, Cancer research.

[59]  R K Jain,et al.  Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[60]  J. Sheu,et al.  Albumin messenger RNA is not specific for circulating hepatoma cells. , 1994, Gastroenterology.

[61]  E. Kohn,et al.  Cancer invasion and metastasis. , 1993, Hospital practice.

[62]  T. Fehm,et al.  A pooled analysis of bone marrow micrometastasis in breast cancer. , 2005, The New England journal of medicine.

[63]  Alessandro Lugli,et al.  Frequent EpCam protein expression in human carcinomas. , 2004, Human pathology.

[64]  G. Dölken,et al.  Detection and monitoring of minimal residual disease by quantitative real-time PCR. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[65]  J. Pouysségur,et al.  Hypoxia signalling in cancer and approaches to enforce tumour regression , 2006, Nature.

[66]  K. Luzzi,et al.  Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. , 1998, The American journal of pathology.

[67]  D. Hayes,et al.  The measurement and therapeutic implications of circulating tumour cells in breast cancer , 2005, British Journal of Cancer.

[68]  H. Depypere,et al.  Molecular targets of growth, differentiation, tissue integrity, and ectopic cell death in cancer cells. , 2005, Cancer biotherapy & radiopharmaceuticals.

[69]  L. Sobin,et al.  International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. , 1999, Cancer.

[70]  Bernard Lacour,et al.  Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer , 2004, Hepatology.

[71]  Joe W Gray,et al.  Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. , 2003, Cancer cell.

[72]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[73]  Tanja Fehm,et al.  HER-2 gene amplification can be acquired as breast cancer progresses. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[74]  D. Sgroi,et al.  Spread of human cancer cells occurs with probabilities indicative of a nongenetic mechanism , 2005, British Journal of Cancer.

[75]  G. T. Budd,et al.  Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival , 2006, Clinical Cancer Research.

[76]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[77]  N. Lane,et al.  Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. , 2005, Cytotherapy.